These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
695 related articles for article (PubMed ID: 24204222)
1. Properties of MHC class I presented peptides that enhance immunogenicity. Calis JJ; Maybeno M; Greenbaum JA; Weiskopf D; De Silva AD; Sette A; Keşmir C; Peters B PLoS Comput Biol; 2013 Oct; 9(10):e1003266. PubMed ID: 24204222 [TBL] [Abstract][Full Text] [Related]
2. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. Yu Z; Theoret MR; Touloukian CE; Surman DR; Garman SC; Feigenbaum L; Baxter TK; Baker BM; Restifo NP J Clin Invest; 2004 Aug; 114(4):551-9. PubMed ID: 15314692 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides. Benichou G; Takizawa PA; Ho PT; Killion CC; Olson CA; McMillan M; Sercarz EE J Exp Med; 1990 Nov; 172(5):1341-6. PubMed ID: 1700053 [TBL] [Abstract][Full Text] [Related]
4. NetMHCstab - predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery. Jørgensen KW; Rasmussen M; Buus S; Nielsen M Immunology; 2014 Jan; 141(1):18-26. PubMed ID: 23927693 [TBL] [Abstract][Full Text] [Related]
5. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238 [TBL] [Abstract][Full Text] [Related]
6. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection. Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. van der Burg SH; Visseren MJ; Brandt RM; Kast WM; Melief CJ J Immunol; 1996 May; 156(9):3308-14. PubMed ID: 8617954 [TBL] [Abstract][Full Text] [Related]
8. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. Levitsky V; Zhang QJ; Levitskaya J; Masucci MG J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295 [TBL] [Abstract][Full Text] [Related]
9. Molecular challenges imposed by MHC-I restricted long epitopes on T cell immunity. Josephs TM; Grant EJ; Gras S Biol Chem; 2017 Aug; 398(9):1027-1036. PubMed ID: 28141543 [TBL] [Abstract][Full Text] [Related]
10. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction. Lairmore MD; DiGeorge AM; Conrad SF; Trevino AV; Lal RB; Kaumaya PT J Virol; 1995 Oct; 69(10):6077-89. PubMed ID: 7545241 [TBL] [Abstract][Full Text] [Related]
11. The canine MHC class Ia allele DLA-88*508:01 presents diverse self- and canine distemper virus-origin peptides of varying length that have a conserved binding motif. Ross P; Nemec PS; Kapatos A; Miller KR; Holmes JC; Suter SE; Buntzman AS; Soderblom EJ; Collins EJ; Hess PR Vet Immunol Immunopathol; 2018 Mar; 197():76-86. PubMed ID: 29475511 [TBL] [Abstract][Full Text] [Related]
13. Targeting HIV-1 Gag into the defective ribosomal product pathway enhances MHC class I antigen presentation and CD8+ T cell activation. Goldwich A; Hahn SS; Schreiber S; Meier S; Kämpgen E; Wagner R; Lutz MB; Schubert U J Immunol; 2008 Jan; 180(1):372-82. PubMed ID: 18097038 [TBL] [Abstract][Full Text] [Related]
14. Leucine aminopeptidase is not essential for trimming peptides in the cytosol or generating epitopes for MHC class I antigen presentation. Towne CF; York IA; Neijssen J; Karow ML; Murphy AJ; Valenzuela DM; Yancopoulos GD; Neefjes JJ; Rock KL J Immunol; 2005 Nov; 175(10):6605-14. PubMed ID: 16272315 [TBL] [Abstract][Full Text] [Related]
15. HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. Goodridge JP; Lee N; Burian A; Pyo CW; Tykodi SS; Warren EH; Yee C; Riddell SR; Geraghty DE J Immunol; 2013 Aug; 191(4):1567-77. PubMed ID: 23851683 [TBL] [Abstract][Full Text] [Related]
16. Puromycin-sensitive aminopeptidase limits MHC class I presentation in dendritic cells but does not affect CD8 T cell responses during viral infections. Towne CF; York IA; Neijssen J; Karow ML; Murphy AJ; Valenzuela DM; Yancopoulos GD; Neefjes JJ; Rock KL J Immunol; 2008 Feb; 180(3):1704-12. PubMed ID: 18209067 [TBL] [Abstract][Full Text] [Related]
17. POPI: predicting immunogenicity of MHC class I binding peptides by mining informative physicochemical properties. Tung CW; Ho SY Bioinformatics; 2007 Apr; 23(8):942-9. PubMed ID: 17384427 [TBL] [Abstract][Full Text] [Related]
18. Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection. García AM; Ortíz-Navarrete VF; Mora-García ML; Flores-Borja F; Diaz-Quiñonez A; Isibasi-Araujo A; Trejo-Becerril C; Chacón-Salinas R; Hernández-Montes J; Granados-Arreola J; de Leo C; Weiss-Steider B Immunol Lett; 1999 Apr; 67(3):167-77. PubMed ID: 10369123 [TBL] [Abstract][Full Text] [Related]
19. Identification of the cognate peptide-MHC target of T cell receptors using molecular modeling and force field scoring. Lanzarotti E; Marcatili P; Nielsen M Mol Immunol; 2018 Feb; 94():91-97. PubMed ID: 29288899 [TBL] [Abstract][Full Text] [Related]
20. Structure of peptides associated with MHC class I molecules. Engelhard VH Curr Opin Immunol; 1994 Feb; 6(1):13-23. PubMed ID: 7513522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]